DEF 14A: Atai Life Sciences N.V. Announces Annual General Meeting of Shareholders

Atai Life Sciences N.V. will hold its Annual General Meeting of Shareholders on May 17, 2024, to vote on key proposals including the adoption of annual accounts, appointment of auditors, director appointments, and extension of share issuance authorizations.

Summary

• Atai Life Sciences N.V. is holding its Annual General Meeting of Shareholders on May 17, 2024, at 6:00 p.m. (Central European Summer Time).
• The meeting will be a hybrid event, allowing shareholders to attend virtually or in person in Amsterdam, The Netherlands.
• Shareholders can submit questions in advance or during the meeting via the online platform.
• The agenda includes proposals such as adopting the 2023 Dutch statutory annual accounts, appointing Deloitte & Touche LLP and Deloitte Accountants B.V. as external auditors for 2024, and releasing board members from liability for their duties during fiscal year 2023.
• The meeting will also include votes on the re-appointment of Christian Angermayer as a supervisory director and the appointment of Scott Braunstein, M.D., Laurent Fischer, M.D., and Raymond Sanchez, M.D. as supervisory directors.
• Additionally, shareholders will vote on the appointment of Anne Johnson as a managing director and the extension of the management board's authorization to issue shares, limit pre-emption rights, and acquire shares.
• The record date for the meeting is April 19, 2024, and shareholders must notify the company of their intention to attend by May 15, 2024.
• As of April 19, 2024, there were approximately 167,412,657 common shares outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and informative tone. The proposals are generally routine corporate governance matters, suggesting a stable and well-managed company.

Positives

• The hybrid meeting format allows for increased shareholder participation from around the world.
• Shareholders have the opportunity to submit questions in advance and during the meeting.
• The agenda includes routine corporate governance matters such as auditor appointment and director re-election.
• The company is seeking to extend authorizations for share issuance and acquisition, providing flexibility for future capital management.

Risks

• Failure to achieve a quorum (one-third of outstanding shares) could prevent the valid passage of voting items.
• The binding nominations for director appointments could be overruled if at least two-thirds of the votes cast, representing more than half of the company's issued share capital, vote against the re-appointment.
• Forward-looking statements are subject to risks and uncertainties detailed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Future Outlook

The company's future performance is subject to various factors outlined in its Annual Report on Form 10-K, and shareholders should not rely on forward-looking statements as predictions of future events.

Management Comments

• Christian Angermayer, Chairman, and Florian Brand, Chief Executive Officer, cordially invited shareholders to attend the Annual General Meeting and urged them to vote their shares.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring shareholders have the opportunity to vote on key decisions and appointments.

Comparison to Industry Standards

• The proposals outlined in the proxy statement are typical for publicly traded companies in the pharmaceutical and biotechnology industries.
• The hybrid meeting format is increasingly common, reflecting a trend towards greater accessibility and shareholder engagement.
• The director qualifications and committee structures appear consistent with Nasdaq listing requirements and best practices in corporate governance.

Management Changes

Related Party Transactions

• Between November 2018 and October 2020, we issued 1.0 million convertible notes at a purchase price of 1.00 per note, with an exercise price of 17.00 per note, for an aggregate subscription price of 1.0 million and additional aggregate proceeds that we would receive upon exercise of 17.0 million.
• In April 2024, Apeiron and ATAI Life Sciences NV executed an exchange agreement (2024 Exchange Agreement) where Apeiron agreed to exchange its 2020 convertible notes issued by ATAI Life Sciences AG (the Old AG Notes) into the same principal amount and number of new convertible notes issued by ATAI Life Sciences N.V. (the New NV Notes) subject to the same financial terms and conditions for no additional consideration.
• On January 16, 2021, ATAI AG entered into a consulting agreement (the Original Consultancy Agreement) with Christian Angermayer, one of our co-founders and chairman of our board of supervisory directors.
• On January 7, 2024, we entered into a Termination and New Consultancy Agreement (the 2024 Consultancy Agreement) with Mr. Angermayer.
• In connection with our initial public offering in June 2021, the underwriters reserved a portion of the common shares for sale to our managing directors, supervisory directors and others.
• Our articles of association require us to indemnify our current and former managing directors and supervisory directors to the fullest extent permitted by law, subject to certain exceptions.
• We have entered into employment agreements with all of our managing directors.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting on key proposals.
• Employees may be affected by changes in executive compensation and management structure.
• The company's performance and strategic decisions impact investors, customers, and other stakeholders.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will announce the voting results in a Current Report on Form 8-K within four business days of the Annual General Meeting.

Key Dates

Keywords

Annual General Meeting, Shareholders, Proxy Statement, Supervisory Directors, Managing Directors, Auditors, Share Issuance, Atai Life Sciences